Roche’s portfolio of immunohistochemistry (IHC) and in situ hybridization (ISH) breast cancer diagnostic assays provide high sensitivity, specificity and consistency. We continue to innovate to broaden clinical utility of these assays to include new indications – and support clinicians in making decisions that lead to better care for more patients.
Here are five reasons why the Roche HER2 (4B5) assay1 remains the trusted IHC predictive assay of choice for laboratories and clinicians alike.